A pilot trial of a carcinoembryonic antigen/TRICOM-based vaccine and radiation to liver metastases in patients with carcinoembryonic antigen-positive solid tumors

Clinical Colorectal Cancer

Volumn 6, Issue 1, 2006, Pages 72-75

  Ahlers, Christoph M ^a   Camphausen, Kevin ^a   Citrin, Deborah ^a   Arlen, Philip M ^a   Gulley, James L ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Adenocarcinoma; Clinical trials; Fas; Granulocyte macrophage colony stimulating factor

Indexed keywords

CANCER VACCINE; CARCINOEMBRYONIC ANTIGEN; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR;

ARTICLE; CANCER ADJUVANT THERAPY; CANCER IMMUNIZATION; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG SAFETY; DRUG TOLERABILITY; EXTERNAL BEAM RADIOTHERAPY; FATIGUE; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; HUMAN; IN VIVO STUDY; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE REACTION; LIVER METASTASIS; LYMPHADENOPATHY; PHASE 1 CLINICAL TRIAL; PILOT STUDY; SOLID TUMOR;

EID: 33745920149     PISSN: 15330028     EISSN: None     Source Type: Journal    
DOI: 10.3816/CCC.2006.n.025     Document Type: Article

References (31)

1. Rogers GT. Carcinoembryonic antigens and related glycoproteins - molecular aspects and specificity. Biochimica et Biophysica Acta 1983; 695:227-249.
2. Muraro R, Wunderlich D, Thor A, et al. Definition by monoclonal-antibodies of a repertoire of epitopes on carcinoembryonic antigen differentially expressed in human- colon carcinomas versus normal adult tissues. Cancer Res 1985; 45:5769-5780.
3. Steward AM, Nixon D, Zamcheck N, et al. Carcinoembryonic antigen in breast cancer patients: serum levels and disease progress. Cancer 1974; 33:1246-1252.
4. Vincent RG, Chu TM. Carcinoembryonic antigen in patients with carcinoma of the lung. J Thorac Cardiovasc Surg 1973; 66:320-328.
5. Ladenson JH, Mcdonald JM, Landt M, et al. Colorectal-carcinoma and carcinoembryonic antigen (CEA). Clin Chem 1980; 26:1213-1220.
6. Jemal A, Siegel R, Ward E, et al. Cancer Statistics, 2006. CA Cancer J Clin 2006; 56:106-130.
7. Scheithauer W, Kornek GV, Brugger S, et al. Randomized phase II study of irinotecan plus mitomycin C vs. oxaliplatin plus mitomycin C in patients with advanced fluoropyrimidine/leucovorin-pretreated colorectal cancer. Cancer Invest 2002; 20:60-68.
8. Scheithauer W, Kornek GV, Schuell B, et al. Second-line treatment with oxaliplatin + raltitrexed in patients with advanced colorectal cancer failing fluoropyrimidine/leucovorin-based chemotherapy. Ann Oncol 2001; 12:709-714.
9. Falcone A, Masi G, Allegrini G, et al. Biweekly chemotherapy with oxaliplatin, irinotecan, infusional fluorouracil, and leucovorin: a pilot study in patients with metastatic colorectal cancer. J Clin Oncol 2002; 20:4006-4014.
10. Carlomagno C, Lauria R, De Laurentiis M, et al. Second-line chemotherapy with a hybrid-alternating regimen of bolus 5FU modulated by methotrexate and infusional 5FU modulated by folinic acid in patients with metastatic colorectal cancer pretreated with 5FU. A phase 2 study. Oncology 2002; 63:219-225.
11. Hegewisch-Becker S, Gruber Y, Corovic A, et al. Whole-body hyperthermia (41.8 degrees C) combined with bimonthly oxaliplatin, high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer: a phase II study. Ann Oncol 2002; 13:1197-1204.
12. Chau I, Webb A, Cunningham D, et al. Oxaliplatin and protracted venous infusion of 5-fluorouracil in patients with advanced or relapsed 5-fluorouracil pretreated colorectal cancer. Br J Cancer 2001; 85:1258-1264.
13. Russell AH, Clyde C, Wasserman TH, et al. Accelerated hyperfractionated hepatic irradiation in the management of patients with liver metastases: results of the RTOG dose escalating protocol. Int J Radiat Oncol Biol Phys 1993; 27:117-123.
14. Greiner JW, Zeytin H, Anver MR, et al. Vaccine-based therapy directed against carcinoembryonic antigen demonstrates antitumor activity on spontaneous intestinal tumors in the absence of autoimmunity. Cancer Res 2002; 62:6944-6951.
15. Guadagni F, Roselli M, Cosimelli M, et al. Quantitative analysis of CEA expression in colorectal adenocarcinoma and serum: lack of correlation. Int J Cancer 1997; 72:949-954.
16. Schlom J, Panicali D. Recombinant poxvirus vaccines. In: Rosenberg SA, editor. Biologic Therapy of Cancer: Principles and Practices. Philadelphia, PA: J.B. Lippincott Co; 2000:686-694.
17. Grosenbach DW, Barrientos JC, Schlom J, et al. Synergy of vaccine strategies to amplify antigen-specific immune responses and antitumor effects. Cancer Res 2001; 61:4497-4505.
18. Hodge JW, Grosenbach DW, Aarts WM, et al. Vaccine therapy of established tumors in the absence of autoimmunity. Clin Cancer Res 2003; 9:1837.
19. Tsang KY, Zhu MZ, Even J, et al. The infection of human dendritic cells with recombinant avipox vectors expressing a costimulatory molecule transgene (CD80) to enhance the activation of antigen-specific cytolytic T cells. Cancer Res 2001; 61:7568-7576.
20. Grosenbach DW, Barrientos JC, Schlom J, et al. Synergy of vaccine strategies to amplify antigen-specific immune responses and antitumor effects. Cancer Res 2001; 61:4497-4505.
21. Zhu MZ, Terasawa H, Gulley J, et al. Enhanced activation of human T cells via avipox vector-mediated hyperexpression of a triad of costimulatory molecules in human dendritic cells. Cancer Res 2001; 61:3725-3734.
22. Aarts WM, Schlom J, Hodge JW. Vector-based vaccine/cytokine combination therapy to enhance induction of immune responses to a self-antigen and antitumor activity. Cancer Res 2002; 62:5770-5777.
23. Hodge JW, Grosenbach DW, Rad AN, et al. Enhancing the potency of peptide-pulsed antigen presenting cells by vector-driven hyperexpression of a triad of costimulatory molecules. Vaccine 2001; 19:3552-3567.
24. Hodge JW, Sabzevari H, Yafal AG, et al. A triad of costimulatory molecules synergize to amplify T-cell activation. Cancer Res 1999; 59:5800-5807.
25. Hodge JW, Rad AN, Grosenbach DW, et al. Enhanced activation of T cells by dendritic cells engineered to hyperexpress a triad of costimulatory molecules. J Natl Cancer Inst 2000; 92:1228-1239.
26. Oh S, Hodge JW, Ahlers JD, et al. Selective induction of high avidity CTL by altering the balance of signals from APC. J Immunol 2003; 170:2523-2530.
27. Chakraborty M, Abrams SI, Coleman CN, et al. External beam radiation of tumors alters phenotype of tumor cells to render them susceptible to vaccine mediated T-cell killing. Cancer Res 2004; 64:4328-4337.
28. Garnett CT, Palena C, Chakraborty M, et al. Sublethal irradiation of human tumor cells modulates phenotype resulting in enhanced killing by cytotoxic T lymphocytes. Cancer Res 2004; 64:7985-7994.
29. Gulley JL, Arlen PM, Bastian A, et al. Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer. Clin Cancer Res 2005; 11:3353-3362.
30. Marshall J, Odogwu L, Hwang J, et al. A phase I study of sequential vaccinations with fowlpox-CEA (6D)-TRICOM (B7/ICAM/LFA3) alone, and in combination with vaccinia-CEA (6D)-TRICOM and GM-CSF in patients with CEA expressing carcinomas. Proc Am Soc Clin Oncol 2003; 23:165 (Abstract #662).
31. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92:205-216.